Evicenter
MarkdownMedical informationP&T meetings
Obefazimod (ABX464)

Ulcerative colitis

Manufacturer
Abivax
Launch
Not announced
Last updated
173 sources

Product information and disease descriptionPlace of product in therapyApproaches to treatmentCurrent treatment options and standard of care

Janus kinase inhibitors

9 evidence topics · 11 sources

Pivotal trial results for tofacitinib and upadacitinib: ACG 2025 evidence summary

“In both trials, clinical remission at week 8 occurred in a significantly higher proportion of patients treated with tofacitinib 10 mg twice a day (BID) (18.5% and 16.6%, respectively) compared with those receiving placebo (8.2% and 3.6%, respectively).” (opens the source at this quote in a new tab)

“At 52 weeks, in the maintenance trial, 40.6% of patients treated with tofacitinib 10 mg BID and 34.3% of patients treated with 5 mg BID achieved remission compared with 11.1% of those treated with placebo.” (opens the source at this quote in a new tab)

“In the U-ACHIEVE induction study, 26% of patients treated with upadacitinib achieved clinical remission compared with 5% of patients receiving placebo (P < 0.0001). In the U-ACCOMPLISH trial, 34% of patients receiving upadacitinib achieved clinical remission at 8 weeks compared with 4% of patients on placebo (P < 0.0001).” (opens the source at this quote in a new tab)

“At the end of follow-up, clinical remission was achieved by a larger proportion of patients treated with upadacitinib 15 mg/d (42%) or 30 mg/d (52%) compared with placebo (12%; P < 0.0001 for both).” (opens the source at this quote in a new tab)

“Filgotinib is an additional JAK-1 selective inhibitor which has demonstrated efficacy in moderately to severely active UC and is approved for use for this indication in Europe (204). However, this therapy is not available in the United States.” (opens the source at this quote in a new tab)

Network meta-analyses: rankings of Janus kinase inhibitors